Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pandemic Preparedness

This article was originally published in Start Up

Executive Summary

Kleiner Perkins Caufield & Byers announced their newest fund for pandemic preparedness Feb 16,2006. The fund's potential to do good is enormous, but skeptics question whether or not it can make money.

You may also be interested in...



Enigma Diagnostics Ltd.

The key to combating an infectious disease threat, be it an individual case of Chlamydia or the global threat of bioterrorism or pandemic avian flu, is rapid on-site diagnosis, enabling physicians to treat--or public health professionals to contain--the disease. One solution is the use of the gold standard test for biological agents, real-time polymerase chain reaction testing. Enigma Diagnostics Ltd. says it is the first UK company to take this technique out of the laboratory and into the field.

Embracing Early-Stage Platform Opportunities at Polaris Ventures

In an interview with START-UP, Polaris Ventures managing partner Terry McGuire discusses recent investment opportunities and his firm's approach to platform technologies in the life sciences. Topics covered include: diagnostics, community diseases, next-generation biologics, and fund diversification.

Embracing Early-Stage Platform Opportunities at Polaris Ventures

In an interview with START-UP, Polaris Ventures managing partner Terry McGuire discusses recent investment opportunities and his firm's approach to platform technologies in the life sciences. Topics covered include: diagnostics, community diseases, next-generation biologics, and fund diversification.

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

SC091231

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel